Introduction
============

The hypertensive pregnancy disorder preeclampsia is one of the most common causes of maternal and fetal morbidity and mortality in the developed world ([@B60]; [@B74]). Impaired placental development early in pregnancy and consequent release of several placenta-derived factors into the maternal circulation is thought to lead to generalized maternal endothelial dysfunction as a main clinical feature in the second half of pregnancy ([@B15]; [@B46]; [@B59]).

Recent studies suggest that preeclampsia not only represents an independent, cardiovascular risk factor for the mother, but that the cardiovascular system of the offspring is also adversely affected. The affected children display on average significantly higher blood pressure, higher body mass index (BMI) and increased vascular stiffness in the pulmonary and peripheral circulation compared to offspring from uncomplicated pregnancies ([@B35]; [@B17]). Epidemiological studies suggest that cardiovascular disease can originate during fetal development ([@B6]). The exact molecular mechanisms are still unclear, but epigenetic changes may be involved.

Endothelial progenitor cells (EPC) play an important role in vascular homeostasis and development, including repair of injured endothelium, angiogenesis, and neovascularization ([@B51]). A decreased cell number of early outgrowth, hematopoietic EPCs in the maternal circulation has been described as a potential sign of impaired endothelial repair capacity in preeclampsia ([@B41]; [@B43]). We previously found lower numbers and impaired function of fetal endothelial colony forming cells (ECFC), a late outgrowth sub-class of EPC, in pregnancies complicated by preeclampsia. ECFCs are a relatively homogeneous cell population able to proliferate and migrate to sites of vessel formation where they are directly involved in building the endothelium ([@B33]; [@B72]). They are critical to, and play a complementary role with other EPCs, in blood vessel formation and repair ([@B64]), and they have been implicated as biomarkers for cardiovascular risk ([@B19]; [@B34]).

Studies on epigenetic modifications in complicated pregnancies are urgently needed to develop epigenetically based therapeutics for the prevention and therapy of early cardiovascular alterations. Considering the potential of cell therapies based on EPCs, the aims of this study were to compare the DNA methylation status of fetal ECFCs at birth between uncomplicated and preeclamptic pregnancies, and to assess the effect of cell culture on DNA methylation.

Materials and Methods {#s1}
=====================

Patients
--------

The Ethical Committee at Hannover Medical School and the University of Pittsburgh Institutional Review Board approved the study. Informed written consent was obtained from each study participant. Twelve healthy women with uncomplicated, normotensive pregnancies (controls) and 12 women with late-onset preeclampsia (diagnosis at \>37 weeks gestation) provided umbilical cord blood samples directly after delivery. Clinical and demographic data of these women are presented in [Table 1](#T1){ref-type="table"}. All had singleton pregnancies. Patients were frequency (group) matched for gestational age at the time of delivery, BMI and race. Patients with preeclampsia had gestational hypertension and proteinuria beginning after 20 weeks of pregnancy with resolution of clinical symptoms postpartum ([@B1]). Gestational hypertension was recognized as an absolute blood pressure ≥ 140 mmHg systolic and/or ≥ 90 mmHg diastolic after 20 weeks of gestation. Proteinuria was defined as ≥ 300 mg per 24h urine collection, ≥ 2+ protein on a voided urine sample, ≥ 1+ protein on a catheterized urine specimen, or a protein-creatinine ratio of ≥0.3. Women with uncomplicated pregnancies were normotensive and without proteinuria throughout gestation, and delivered healthy babies at term. All patients were without clinical history of preexisting renal, vascular, or metabolic disease.

###### 

Patient demographics.

                                                     Uncomplicated pregnancy (*n* = 12)   Preeclamptic pregnancy (*n* = 12)   *p* value
  -------------------------------------------------- ------------------------------------ ----------------------------------- -----------------
  Maternal age (years)                               29.3 ± 6.1                           28.6 ± 5.6                          0.76
  Gestational age at delivery (weeks)                39.0 ± 0.7                           37.7 ± 2.0                          0.06
  Multiparous *n* (%)                                7 (58%)                              8 (67%)                             1.0
  Maternal pre-pregnancy BMI (kg/m^2^)               25.4 ± 5.1                           27.8 ± 9.8                          0.47
  Gestational SBP, pre-delivery (mmHg)               122 ± 9.6                            153 ± 19.5                          **\<0.0001^∗^**
  Gestational SBP, before 20 week gestation (mmHg)   114 ± 13.6                           122 ± 15.8                          0.18
  Gestational DBP, pre-delivery (mmHg)               73.4 ± 8.2                           93.6 ± 9.8                          **\<0.0001^∗^**
  Gestational DBP, before 20 week gestation (mmHg)   70.4 ± 10.5                          76.5 ± 10.2                         0.17
  Birth weight (g)                                   3467 ± 417                           2848 ± 645                          **0.01^∗^**
  Birth weight percentile                            49.2 ± 28.5                          29.8 ± 26.2                         0.1
  Birth weight percentile \< 10th, *n* (%)           0 (0%)                               2 (16.3%)                           0.48
  Cesarean delivery *n* (%)                          9 (75%)                              7 (58%)                             0.42
  Maternal race, White *n* (%)                       10 (83%)                             9 (75%)                             1.0
  Baby sex, Male *n* (%)                             9 (75%)                              5 (42%)                             0.11

Data are expressed as mean ± standard deviation or number (

n

) and %. Distribution was examined with Kolmogorov--Smirnov test. Continuous data were compared with unpaired

t

-test or Mann--Whitney test, as appropriate. Categorical variables were compared by Fisher's exact test. BMI body-mass index; SBP systolic blood pressure; DBP diastolic blood pressure.

ECFC Isolation
--------------

Endothelial colony-forming cells isolation and characterization was performed following previously published protocols ([@B28]; [@B8]). Briefly, peripheral blood mononuclear cells (PBMCs) were isolated from 40 to 50 mL of venous cord blood by gradient centrifugation (1500 rpm, Ficoll Plus, GE Healthcare, Buckinghamshire, England or Piscataway, NJ). The washed PBMCs were plated (5 × 10^7^ cells/well) onto collagen-coated 6-well plates (BD Bioscience, Heidelberg, Germany or Billerica, MA), containing endothelial growth medium-2 (EGM-2, Lonza, Basel, Switzerland) supplemented with suppliers recommended concentrations of growth factors, 10% FBS and 1% penicillin/streptomycin. Growth media were changed daily for the first seven days and then every other day. Colonies were assessed daily, and colony numbers and time of colony appearance were recorded. Colonies were then clonally expanded and banked for the studies as described below. The phenotype of each ECFC clonal line was confirmed by its "cobblestone" monolayer morphology, determination of acetylated low-density lipoprotein uptake and Ulex europaeus lectin binding, capillary tubule-like network formation in Matrigel assay, expression of characteristic surface markers (CD31, CD34, KDR) and the absence of hematopoietic or myeloid surface antigens (CD45, CD14 and CD133), as previously described ([@B8]).

DNA Sample Preparation
----------------------

Endothelial colony-forming cells at 80--90% confluence were extensively rinsed in cold PBS, mechanically scraped from the flask, snap frozen and stored at --80°C. Further processing was continued for all samples simultaneously. First, 1--5 mg of cells were homogenized using QIAshredder columns (Qiagen, Leipzig, Germany) and genomic DNA and total RNA were isolated from the cell lysates using the AllPrep DNA/RNA micro kit (Qiagen, Leipzig, Germany).

Methylation Analysis
--------------------

DNA samples were subjected to methylation analyses using the Illumina Infinium EPIC BeadChip Kit (Illumina, San Diego, CA, United States) at the University of Kiel, Institute of Clinical Molecular Biology (ICMB). Native DNA was sent from our lab to ICMB. The samples were coded for blinded sample analysis by ICMB personnel. The assay required 200 ng of original DNA sample as input. The DNA samples were denatured and neutralized and were then isothermally amplified in an overnight step. The whole-genome amplification uniformly increased the amount of the DNA sample by several thousand-fold without significant amplification bias. A controlled enzymatic process fragmented the amplified product. The process used endpoint fragmentation to prevent overfragmentation. The fragmented DNA was collected after an isopropanol precipitation and centrifugation at 4°C. The precipitated DNA was resuspended in hybridization buffer. Samples were applied to a BeadChip and separated by an IntelliHyb seal. The loaded BeadChip was incubated overnight in an Illumina Hybridization Oven. The amplified and fragmented DNA samples annealed to locus-specific 50-mers during hybridization. Unhybridized and non-specifically hybridized DNA was washed off and the BeadChip was prepared for staining and extension. Single-base extension of the oligos on the BeadChip, using the captured DNA as a template, incorporated detectable labels on the BeadChip and determined the genotype call for the sample. XStain occurred in a capillary flow-through chamber. The Illumina HiScan System scanned the BeadChip, using a laser to excite the fluorophore of the single-base extension product on the beads. The scanner recorded high- resolution images of the light emitted from the fluorophores. Processed data were sent back to our lab for analysis.

Network and Pathway Analysis
----------------------------

We compared methylated genes from preeclampsia versus uncomplicated pregnancy at passage 3 or passage 5 using the database of the Gene Ontology (GO) Consortium ^[1](#fn01){ref-type="fn"}^ ([@B27]) for an enrichment of biological pathways as defined in the Kyoto Encyclopedia of Genes and Genomes (KEGG) database ^[2](#fn02){ref-type="fn"}^ ([@B36]), and for predominant protein-protein interaction networks according to the STRING database ([@B68]). These resources are publicly accessible and implemented in STRING ^[3](#fn03){ref-type="fn"}^. For our analyses, we used STRING at the level of highest confidence (0.900), with protein-protein interactions restricted to experimental evidence, and without addition of interactors at the first or second shell. Biological processes or pathways were considered significantly enriched after correction for multiple testing if the false discovery rate (FDR) was FDR \< 0.05. Enrichment of GO processes was additionally validated in an independent analysis using the newest version 14.0 of the PANTHER (Protein ANalysis THrough Evolutionary Relationship) resource ([@B49]).

Additional analysis of networks and pathways were conducted using the commercial Ingenuity Pathway Analysis (IPA) software tool (Qiagen, Hilden, Germany). The standard setup for network analysis provided by the IPA core analysis was employed. The "molecules per network" parameter was set at 70, because of the large amount of input genes. All genes carrying single and multiple methylated CpG dinucleotides were used for the IPA analysis.

Statistical Analysis
--------------------

Statistical analysis of the Illumina methylation bead array data was performed separately for cell culture passage 3 and 5 with the R software (R version 3.5.0; R Core Team) following the analysis pipeline provided by the ChAMP package ([@B50]); probes were filtered for detection *p*-values above 0.01 removing 3334 probes. Overall, no completely failed measurements were identified. Using general EPIC SNP list for filtering probes with SNPs as identified by [@B82], 79762 probes were excluded from further analysis. Furthermore, 49 samples associated with more than one location as identified by [@B52] were removed. Finally, the samples located on the X and Y chromosome were excluded from further analysis. Type-2 probe correction was carried out with the BMIQ method ([@B69]). There were no significant batch effects to correct. After purification of the data the genomic methylation pattern of fetal ECFC from preeclamptic and uncomplicated control pregnancies, at low and advanced cell culture passages, were compared. For the identification of Differentially Methylated Regions (DMR) Probe Lasso method was used ([@B10]).

Results
=======

Differentially Methylated CpG Regions in Cord Blood ECFC Associated With Maternal Preeclampsia
----------------------------------------------------------------------------------------------

We first compared the methylation patterns of cord blood derived ECFC associated with preeclampsia and normal pregnancy controls by means of the Infinium EPIC BeadChip microarray. This methylome analysis identified a number of differently regulated CpG sites, the majority of which were hypomethylated in fetal ECFCs from preeclamptic compared to control pregnancies.

In cell passage 3 a total of 346 hypermethylated and 920 hypomethylated CpG dinucleotides were identified in the preeclamptic group compared to the control group. Thirty out of 346 hypermethylated and 204 out of 920 hypomethylated CpGs mapped to regions not associated with any known gene. We identified 316 out of 346 hypermethylated and 716 out of 920 hypomethylated CpG dinucleotides that mapped in or near 954 known genes ([Figure 1](#F1){ref-type="fig"}). Of these 954 genes, 891 were affected by a single altered CpG site. Sixty-three genes were altered by 2 or more sites. [Figure 2A](#F2){ref-type="fig"} shows the 70 most differently methylated genes in the preeclamptic group compared to the control group.

![Distribution of the differentially methylated CpG dinucleotides in ECFC from pregnancies complicated by preeclampsia vs. controls. Top panel all differentially methylated CpG dinucleotides; mid panel hypomethylated CpG dinucleotides; bottom panel hypermethylated CpG dinucleotides. The exploded portion of the pie charts report the classification of those differentially methylated CpG dinucleotides that map in or near know genes. The other portion of the pie chart reports the main characteristics of the differentially methylated CpG dinucleotides that do not map in or near known genes.](fcell-07-00032-g001){#F1}

![Representation of the 70 mostly methylated genes. The number of methylation sites is plotted on the *Y* axis. The gene name can be found on the *X* axis. **(A)** Cell passage 3; **(B)**: Cell passage 5.](fcell-07-00032-g002){#F2}

In cell culture passage 5 we found 555 hypermethylated and 1807 hypomethylated CpG dinucleotides in the preeclamptic group compared to the control group. Here, 43 out of 555 hypermethylated and 351 out of 1807 hypomethylated CpGs mapped to regions not associated with any known gene. We identified 512 out of 555 hypermethylated and 1456 out of 1807 hypomethylated GpG mapped in or near 1719 known genes ([Figure 1](#F1){ref-type="fig"}). Analogous to cell culture passage 3, 1530 genes were affected by a single altered CpG site and 199 genes were altered by 2 or more sites. [Figure 2B](#F2){ref-type="fig"} shows the 70 most differently methylated genes in the preeclamptic group compared to the control group.

Pathway Analysis Comparing Preeclampsia Derived ECFCs and Controls
------------------------------------------------------------------

We first used STRING to explore the larger set of differentially methylated genes in passage 5 for an enrichment of biological processes according to the GO database. Subsequently we investigated for an enrichment of biological pathways as defined in the KEGG database, and for predominant protein-protein interaction networks. Among 1625 proteins differentially expressed in passage 5, we found a significant enrichment for 382 GO biological processes ([Supplementary Table S1](#SM1){ref-type="supplementary-material"}). There was a marked enrichment for proteins involved in primary metabolic processes (GO: 0044238, FDR 6.75 × 10^-16^), more specifically in the positive regulation of RNA metabolic processes (GO: 0051254, FDR 5.94 × 10^-10^), in cellular protein modification processes (GO: 0006464, FDR 5.29 × 10^-10^), and in the positive regulation of transcription (GO: 0045893, FDR 1.01 × 10^-9^). Consistent with this, the protein-protein interaction clusters with most nodes were observed for proteasomal function, RNA transcription and pre-mRNA splicing ([Figure 3A](#F3){ref-type="fig"}). Enriched biological processes also included cell cycle (GO: 0007049, FDR 2.24 × 10^-9^), cellular nitrogen compound metabolism (GO: 0034641, FDR 1.04 × 10^-6^), adherens junction assembly (GO: 0034333, FDR 9.27 × 10^-5^), chromatin modification (GO: 0016568, FDR 1.27 × 10^-4^), cellular response to growth factor stimulus (GO: 0071363, FDR 6.23 × 10^-4^) and tube morphogenesis (GO: 0035239, 7.77 × 10^-4^). These observations point to a broad spectrum of enriched cellular developmental processes. KEGG pathway analyses indicated enrichment for 33 biological pathways, with the most significantly enriched pathways related to cell-cell interaction (5205, 4510, 4520, FDR 0.002--0.005), Wnt signaling (4310, FDR 0.003) and mTOR signaling (4150, FDR 0.004) ([Supplementary Table S2](#SM2){ref-type="supplementary-material"}). Estrogen signaling (FDR 0.01) and oxytocin signaling (FDR 0.03) were also among the enriched pathways.

![STRING analysis of protein-protein interaction networks in panel **(A)** Passage 5, and panel **(B)** Passage 3 ECFCs, respectively. In both analyses, three clusters of interacting proteins were identified that were related to proteasomal function, pre-mRNA splicing, and DNA-dependent RNA transcription (from left to right).](fcell-07-00032-g003){#F3}

The smaller subset of 899 proteins differentially expressed in passage 3 recapitulated to a large extent the findings from passage 5, with most pronounced enrichments for proteins involved in primary metabolic processes (GO: 0044238, FDR 8.4 × 10^-9^), cell surface receptor signaling (GO: 0007166, FDR 3.21 × 10^-7^), protein phosphorylation (GO: 0006468, FDR 5.77 × 10^-7^) and cell cycle (GO: 0005049, FDR 5.77 × 10^-7^) ([Supplementary Tables S3](#SM3){ref-type="supplementary-material"}, [S4](#SM4){ref-type="supplementary-material"}). Again, the three most extended protein interaction networks were found for proteins involved in proteasomal, transcriptional and pre-mRNA splicing processes, although the clusters were smaller in concordance with the smaller number of differentially methylated loci in passage 3 ([Figure 3B](#F3){ref-type="fig"}).

We also performed IPA to evaluate and classify genes influenced by significantly altered CpG regions. IPA recognized 552 out of 954 injected genes in cell culture passage 3 and 1038 out of 1719 injected genes in cell culture passage 5. For the creation of a gene network, only the known genetic associations and linkages for mammalian endothelial cells from the IPA database were used. Both the significantly altered CpGs from preeclampsia compared to the control group from cell culture passage 3 and passage 5 were read and evaluated in parallel manner.

The highest-ranking network for cell culture passage 3 was the "Cardiovascular System Development and Function, Organizational Development, Cellular Development" network ([Figure 4A](#F4){ref-type="fig"}). This network comprises 22 genes, of which 6 in the preeclamptic samples are methylated significantly differently in comparison to the control samples (*CDKN1A: hypermethylated at 1 position, EGFR: hypomethylated at 1 position, KRD: hypermethylated at 1 position, S1PR1: hypermethlyated at 1 position, SMAD3: hypomethylated at 1 position, SMAD7: hypermethylated at 1 position*). The most important canonical pathways of the altered genes are summarized in [Table 2](#T2){ref-type="table"}.

![**(A)** Ingenuity pathway analysis (IPA) for the genes included in network of cell culture passage 3. Gene symbol shading: green, hypomethylated; red, hypermethylated; white, no differential methylation. For hyper- and hypomethylated genes, red/green gradient relates to the methylation level. **(B)** IPA canonical pathway analysis for the genes included in network for cell culture passage 3. Canonical pathway red symbol gradient relates to the *p*-value for the likelihood of the association between the differentially methylated genes in our experiment and the pathway. The smaller the *p*-value, the darker the red shading and the stronger the association.](fcell-07-00032-g004){#F4}

###### 

Summary of the ingenuity pathway analysis (IPA) network and pathway analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cell culture passage                               Main Network                                                                                   Main characteristics   Main genes   Other genes   Main pathways                                                  Top upstream regulator
  -------------------------------------------------- ---------------------------------------------------------------------------------------------- ---------------------- ------------ ------------- -------------------------------------------------------------- ------------------------
  3                                                  Cardiovascular System Development and Function, Organismal Development, Cellular Development   Gene (%): 6 (27)\      *SMAD2*\     *ARHGAP22*\   Human Embryonic Stem Cell Pluripotency\                        CXXC5\
                                                                                                                                                    Hypo (%): 2 (9)\       *SMAD3*\     *RASSF5*\     Cell Cycle: G1/S Checkpoint Regulation\                        ENG
                                                                                                                                                    Hyper (%): 4 (18)      *SMAD6*\     *SEMA3C*\     Sphingosine-1-phosphate Signaling\                             
                                                                                                                                                                           *SMAD7*\     *PTPRZ1*\     ERK5 Signaling\                                                
                                                                                                                                                                           *S1PR1*\     *SLC29A1*\    Glucose and Glucose-1phosphate Degradation\                    
                                                                                                                                                                           *S1PR4*\     *PDGFD*\      GDP-glucose Biosynthesis                                       
                                                                                                                                                                           *KDR*\       *CD2AP*\                                                                     
                                                                                                                                                                           *MEF2*\      *OSMR*\                                                                      
                                                                                                                                                                           *PDGF*\      *SCARB1*\                                                                    
                                                                                                                                                                           *p21*\       *PLXNB2*\                                                                    
                                                                                                                                                                           *EGFR*\      *LTBP1*\                                                                     
                                                                                                                                                                           GCK          *PLD1*\                                                                      
                                                                                                                                                                                        *FERMT3*\                                                                    
                                                                                                                                                                                        *CLK3*\                                                                      
                                                                                                                                                                                        *ADAM10*\                                                                    
                                                                                                                                                                                        *BCAR3*\                                                                     
                                                                                                                                                                                        *EDG*\                                                                       

  5                                                  Cardiovascular System Development and Function, Organismal Development, Cellular Development   Gene (%): 13 (30)\     *SMAD2*\     *SDC4*\       Human Embryonic Stem Cell Pluripotency\                        BMPR2\
                                                                                                                                                    Hypo (%): 6 (14)\      *SMAD3*\     *RASSF5*\     Cell Cycle: G1/S Checkpoint Regulation\                        ERG\
                                                                                                                                                    Hyper (%): 7 (16)      *SMAD6*\     *PTH1R*\      Sphingosine-1-phosphate Signaling\                             CXXC5
                                                                                                                                                                           *SMAD7*\     *PTPRZ1*\     ERK5 Signaling\                                                
                                                                                                                                                                           *S1PR1*\     *CBP*\        Phospholipase C Signaling\                                     
                                                                                                                                                                           *S1PR4*\     *CREB*\       Protein Kinase A Signaling\                                    
                                                                                                                                                                           *KDR*\       *PLD*\        Regulation of the Epithelial-Mesenchymal Transition Pathway\   
                                                                                                                                                                           *MEF2*\      *ITGB1*\      Glucose and Glucose-1phosphate Degradation\                    
                                                                                                                                                                           *CDKN1A*\    *SEMA3C*\     GDP-glucose Biosynthesis ERK5 Signaling                        
                                                                                                                                                                           *JAG2*\      *ARHGAP22*\                                                                  
                                                                                                                                                                           *EGFR*       *PLPP3*\                                                                     
                                                                                                                                                                                        *FLNB*\                                                                      
                                                                                                                                                                                        *CD2AP*\                                                                     
                                                                                                                                                                                        *FLNB*\                                                                      
                                                                                                                                                                                        *OSMR*\                                                                      
                                                                                                                                                                                        *ALCAM*\                                                                     
                                                                                                                                                                                        *SCARB1*\                                                                    
                                                                                                                                                                                        *PLXNB2*\                                                                    
                                                                                                                                                                                        *LTBP1*\                                                                     
                                                                                                                                                                                        *IL15*\                                                                      
                                                                                                                                                                                        *ZDHHC7*                                                                     

  Genes changed in passage 5, but not in passage 3   Cellular Development, Cellular Function and Maintenance, Cellular Growth and Proliferation                            *CREB*\      *SDC4*\       G-alpha Signaling\                                             ERG
                                                                                                                                                                           *GPCR*\      *PTH1R*\      Rho GDI Signaling\                                             
                                                                                                                                                                           *CBP*\       *ITGB1*\      Granzyme A Signaling                                           
                                                                                                                                                                           *SMAD4*      *CLK3*\                                                                      
                                                                                                                                                                                        *SCUBE2*\                                                                    
                                                                                                                                                                                        *SLC2A6*\                                                                    
                                                                                                                                                                                        *FLNB*\                                                                      
                                                                                                                                                                                        *ALCAM*\                                                                     
                                                                                                                                                                                        *IL15*\                                                                      
                                                                                                                                                                                        *ZDHHC7*\                                                                    
                                                                                                                                                                                        *LTBP2*\                                                                     
                                                                                                                                                                                        *JAG2*\                                                                      
                                                                                                                                                                                        *PEG10*\                                                                     
                                                                                                                                                                                        *ADGRG1*\                                                                    
                                                                                                                                                                                        *COL4A1*\                                                                    
                                                                                                                                                                                        *PLXNB1*                                                                     
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Genes (%) = number and percent of the genes of each network belonging to the list of genes carrying differentially methylated CpG dinucleotides from this study; Hypo (%) = number and percentage of genes carrying hypomethylated CpG dinucleotides (percentage calculated over the per-network total number of genes carrying differentially methylated CpG dinucleotides from this study); Hyper (%) = number and percentage of genes carrying hypermethylated CpG dinucleotides (percentage calculated over the per-network total number of genes carrying differentially methylated CpG dinucleotides from this study). Genes are reported in capital letters italicized; domains are reported as per the IPA notation.

The canonical pathway analysis of the IPA data yielded 2 main webs ([Figure 4B](#F4){ref-type="fig"}). The most influential and central pathway of the first web was "Human Embryonic Stem Cell Pluripotency," a pathway with an important role in cell growth, proliferation and development. In the preeclamptic group compared to controls, *SMAD3* was significantly hypomethylated and *SMAD7* hypermethylated. SMAD activity is also part of the second pathway called "Cell Cycle: G1/S Checkpoint Regulation." For instance, preeclampsia was associated with a hypermethylation of *CDKN1A*, encoding the cyclin dependent kinase inhibitor p21^Waf1/Cip1^. Further pathways in web 1 included "Sphingosine-1-phosphate Signaling" and "ERK5 Signaling."

The second web was dominated by glucose metabolism, especially glucose and glucose-1-phosphate degradation and GDP-glucose biosynthesis.

Patterns in cell culture passage 5 were similar to cell culture passage 3. Again, the highest-ranking network was "Cardiovascular System Development and Function, Organizational Development, Cellular Development" ([Figure 5A](#F5){ref-type="fig"}), comprising 44 genes, of which seven were hypermethylated and six genes were hypomethylated. The canonical pathway analysis yielded results similar to cell culture passage 3 ([Figure 5B](#F5){ref-type="fig"}). However, pathway web 1 was extended by the pathway "protein kinase A signaling" and "phospholipase C signaling." An additional significant epigenetic change detected in cell culture passage 5 but not yet in cell culture passage 3 was the pathway called "regulation of the epithelial-mesenchymal transition pathway." In the preeclamptic setting PDGF was hypermethylated and EGFR hypomethylated, changes with potential to trigger a mesenchymal phenotype.

![**(A)** Ingenuity pathway analysis (IPA) for the genes included in network of cell culture passage 5. Gene symbol shading: green, hypomethylated; red, hypermethylated; white, no differential methylation. For hyper- and hypomethylated genes, red/green gradient relates to the methylation level. **(B)** IPA canonical pathway analysis for the genes included in network for cell culture passage 5. Canonical pathway red symbol gradient relates to the *p*-value for the likelihood of the association between the differentially methylated genes in our experiment and the pathway. The smaller the *p*-value, the darker the red shading and the stronger the association.](fcell-07-00032-g005){#F5}

Cell Passage Specific Methylation Analysis
------------------------------------------

Among all samples irrespective of pregnancy outcome group, a total of 1096 CpG regions were significantly altered in cell culture passage 5 compared to cell culture passage 3. Of these, 770 were gene-associated. Interestingly, only five gene-associated altered CpG regions, which were detectable in cell culture passage 3, were no longer detectable in passage 5. All other CpGs altered in passage 3 were also significantly altered in passage 5. The overlap between differentially methylated coding genes in passage 3 cells and passage 5 cells and the ratio of the coding genes in passage 3, passage 5 and passages 3 + 5 in percent is shown in [Figure 6](#F6){ref-type="fig"}. By IPA pathway analysis, those genes impacted in passage 5 but not yet in passage 3 were assignable to the domain of "Cellular Development, Cellular Function" and "Maintenance, Cellular Growth and Proliferation." The canonical pathway analysis revealed "G-alpha signaling" (which regulates signal transduction and thus initiates changes in cell behavior) "Rho-GDI signaling" (important for cell differentiation, proliferation and apoptosis), and "Sumoylation pathway" (which plays a role in cell cycle control, trafficking and apoptosis). These pathways can be broadly categorized as intracellular and second messenger signaling, and cellular growth and transcriptional regulation.

![Venn diagram showing the overlap between differentially methylated coding genes in passage 3 cells (left) and passage 5 cells (right). Figure generated using Venny 2.1.0 (<http://bioinfogp.cnb.csic.es/tools/venny>).](fcell-07-00032-g006){#F6}

Discussion
==========

The molecular and cellular dysfunctions associated with preeclampsia are still largely unknown. Here we compared the global DNA methylation profiles of fetal ECFCs from uncomplicated pregnancies and pregnancies complicated by preeclampsia. We identified 954 genes in passage 3 and 1719 genes in passage 5 with significantly differentially methylated CpG sites between the two groups. Almost all changes between the group with preeclampsia and the control group detected in cell culture passage 3 were also confirmed in cell culture passage 5 (1260 out of 1266), indicating that the methylation differences in passage 3 are stably propagated and methylation dysregulation accumulates at later passages. Several studies showed that higher cell passage numbers lead to more inconsistent production of certain biomarkers and methylation levels at least in cancer cells and endocrine cells ([@B38]; [@B29]). An analysis of the effect of cell culture passage revealed very similar results in passage 3 and passage 5 in terms of the profile of the gene networks and the pathways associated with preeclampsia.

Hypermethylation predominantly results in a decrease in gene expression whereas hypomethylation tends to be gene activating ([@B63]). Interestingly, much of the epigenetic changes in our study involved hypomethlylation. This result is consistent with studies of methylation in placentas from women with preeclampsia ([@B80]; [@B7]; [@B44]). These reports indicated a general loss of CpG methylation in preeclampsia placentas, such that the profile was significantly different from normotensive, uncomplicated pregnancies. We found a substantial number of the methylation differences to reside in non-coding regions of the genome. This is unlikely to be unique to our model system given that changes in non-coding regions have been shown to be associated with the overexpression of long non-coding RNAs (lncRNAs) transcripts. These RNAs, characterized as a novel class of non-coding RNAs are linked to human disease and exerting specific functions ([@B45]; [@B76]). In addition, lncRNAs may regulate gene function by influencing splicing, transport, translation or degradation of their corresponding mRNA ([@B79]). Accumulated evidence suggests that many lncRNAs are expressed abnormally in placents from preeclamptic pregnancies and that they may play a role in functional development of preeclampsia ([@B12]; [@B67]; [@B77]).

Our results for both GO biological processes and protein-protein interaction networks indicated that ECFCs from preeclamptic pregnancies are differentially methylated in regions corresponding to a broad range of processes regulating cell metabolism, transcription and cell cycle, with a likely role for protein networks involved in proteasomal, transcriptional and pre-mRNA splicing processes. KEGG pathway analyses pointed to differential regulation of cell-cell interaction, Wnt signaling and mTOR signaling. In regard to preeclampsia, these pathways might be expected to negatively impact the capacity for endothelial development/repair and trophoblast invasion. Our results from IPA, restricted to interactions in mammalian endothelial cells, revealed "Cardiovascular System Development and Function, Organizational Development, Cellular Development" as the highest ranking network.

The methylation pattern of fetal ECFC reveals a unique epigenetic signature which may represent a close link to cardiovascular system development and function and contribute to the cardiovascular risk of offspring born of preeclamptic pregnancies. As this is a study on fetal ECFC we can imagine that epigenetic modules may act as a molecular readout of cumulative cardiovascular risk factor exposure, with implications for the improvement of clinical risk prediction in the future. However, this has never been proven and follow up studies on these children from preeclamptic pregnancies in a larger cohort are clearly necessary. Comprehensive reviews and studies also suggest that changes in DNA methylation states contribute to the regulation of biological processes underlying cardiovascular disease, such as atherosclerosis, hypertension, and inflammation ([@B5]) and several studies in adults show epigenetic associations with incident cardiovascular disease that reveal disease mechanisms ([@B25]; [@B71]). Also, integrated models using genetic, epigenetic and phenotype data are able to detect symptomatic cardiovascular disease ([@B21]). However, we are unaware of any study using methylation data that predicted cardiovascular disease before symptomatic disease occurred.

Studies on the methylation of human gestational tissue, e.g., placental tissue or cells derived from umbilical cord blood are only at the beginning. Therefore, this project is novel in both the cells studied and the implications of fetal progenitor cells for pathogenesis of preeclampsia and its long-term consequences for the offspring. An epigenetically modified endothelial precursor could affect both normal feto-placental vascular development and repair capacity and might influence the subsequent health of the offspring. Although implications for maternal pathogenesis of preeclampsia can not be inferred by our data, there is evidence that fetal ECFCs have a role in normal placental vasculogenesis and further that these cells traverse the placenta and home to sites of vessel formation in the maternal uterine microvasculature ([@B65]).

Our data, while in need of further exploration, suggest involvement of certain pathways in the epigenetic imprinting of preeclampsia in utero. The main canonical pathway implicated deals with embryonic stem cell pluripotency and is regulated by extrinsic and intrinsic factors. Here the regulation of TGF-beta signaling via SMAD proteins is in center. The hypo- and hypermethylation of SMAD coding genes changes in cell differentiation associated with preeclampsia Linked through SMAD activity a second important pathway for cell cycle checkpoint regulation was observed. The key components involved are the cell cycle kinases and the transcription complex. The bioactive sphingosine-1-phosphate has been linked to a wide spectrum of biological processes, including cell growth, survival and motility and forms the bridge to pathway 3. The hypermethylation of this central gene in this pathway can possibly lead to a reduction of cell survival and migration capacity via the described pathway ([@B20]). The ligand sphingosine-1-phosphate also seems to be influenced indirectly via the methylation of platelet derived growth factor (PDGF) and a lack of stimulation of sphingosine-kinase-1 in the preeclamptic setting ([@B66]). Another affected pathway was ERK5 signaling. Typically, it is activated by external stimuli such as serum, growth factors, and cellular stressors including hypoxia and altered osmotic pressure ([@B9]). Simplified, activation results in increased gene expression and cell survival. In the preeclampsia group, two central genes of this pathway, namely the EGF-receptor and the myocyte enhancer factor 2 (MEF2), were hypomethylated, suggesting that a change in gene products and thus activation of the pathway is possible under the stressor preeclampsia. Further pathways were found including glucose and glucose-1-phosphate degradation and GDP-glucose biosynthesis, whose activation may occur with preeclampsia.

Given the potential utility of ECFCs in cell-based therapies, a subanalysis focused on the comparison of two different cell culture passages to assess whether the cell culture passage affects the methylation pattern. Cell culture passage 3 corresponds to the earliest time at which a sufficient number of cells can be harvested after the initial isolation. Passage 5 was chosen as a comparison group, as ECFC at this cell age are commonly used for functional studies. Although the results in cell culture passage 3 and 5 were similar in terms of both the patterns of the gene networks and the pathways, some differences were nevertheless detected. The differentially methylated genes by cell culture passages could be assigned to cellular development, function and maintenance. The canonical analysis revealed pathway differences which regulate signal transduction, cell behavior and differentiation, proliferation and apoptosis. Based on these results, it can be interpreted that the culture of ECFC leads to a change in the methylation profile primarily of cell culture specific pathways. As almost all differences between control group and preeclampsia group detected in cell culture passage 3 were also confirmed in cell culture passage 5 (1260 out of 1266), the gene modification caused by preeclampsia appeared to be largely stable through higher cell culture passages.

IPA results suggest that there are similarities between epigenetic changes in preeclampsia and cardiovascular disease outside the setting of pregnancy. Cardiovascular diseases are complex multifactorial and polygenetic, with interaction of numerous genes, genetic variants, and environmental factors contributing to development ([@B73]). In attempts to demonstrate association between genetic variants and cardiovascular disease, researchers have run large genome wide association studies. In our study, we identified important epigenetic changes already described in the pathogenesis of preeclampsia, or whose activation or inactivation of their gene products fit to well-known or suspected pathways in preeclampsia ([@B4]; [@B3]; [@B2]; [@B48]). We also tabulated altered genes of known relevance to cardiovascular disease ([Table 3](#T3){ref-type="table"}). The principal genes in the analysis could plausibly play a role in preeclampsia pathogenesis and in later future cardiovascular diseases of the offspring.

###### 

Overlapping findings between the existing cardiovascular literature and the work presented in this study.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene; full name                                       Description in NCBI gene data base                                                                                                                                                Known function in preeclampsia                                                                                                                                                                                                Known function in cardiovascular disease                                                                                                                                                                                                       Status in preeclampsia-derived compared to normal pregnancy-derived ECFCs
  ----------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------
  *EGFR*; epidermal growth factor receptor              Cell surface protein that binds to epidermal growth factor. Binding to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation.   Disruption of the EGF signaling system seems to contribute to aberrant trophoblast development ([@B3]).                                                                                                                       EGFR blockade reduces atherosclerosis development ([@B81]).                                                                                                                                                                                    Hypomethylated

  *KDR*; kinase insert domain receptor                  Type III receptor tyrosine kinase that functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting.        VEGFR-1 mediates trophoblast function and inhibits VEGF-induced angiogenesis and endothelium-dependent vasodilation ([@B13]).\                                                                                                VEGF and its receptors play a role in vascular aging, peripheral artery disease, coronary vascular disease and atherosclerotic plaque growth ([@B14]; [@B78]; [@B37]).                                                                         Hypermethylated
                                                                                                                                                                                                                                          Altered tissue expression of VEGF and its receptors are described in the umbilical cord vessels from preeclamptic pregnancies ([@B2]).                                                                                                                                                                                                                                                                                                                                       

  *PDGF*; platelet derived growth factor                Mitogenic factor for cells of mesenchymal origin.                                                                                                                                 PDGF is associated with the pathology of decidual blood vessel. Elevated serum PDGF levels and PDGF-B mRNA expression in the decidual blood vessel may play an important role in the pathogenesis of preeclampsia ([@B47]).   Altered expression of the receptors and the ligands have been found in various cardiovascular diseases and PDGF-C and PDGF-D signaling has been implicated in fibrosis, neovascularization, atherosclerosis and restenosis ([@B23]; [@B39]).   Hypermethylated

  *SMAD2*; SMAD family member 2                         Mediator of transforming growth factor (TGF)-beta, regulating cell proliferation, apoptosis, and differentiation.                                                                 Reduced SMAD2 phosphorylation in a preeclampsia animal model and placental tissues. Endothelial cells may be protected from hypoxia injury through SMAD2 axis ([@B22]).                                                       Regulation of artery size, cardiomyogenesis and vascular smooth muscle cell migration in atherosclerosis ([@B57]; [@B58]; [@B55]).                                                                                                             Hypomethylated

  *S1PR1*/4; sphingosine-1-phosphate receptor 1 and 4   Involved in the processes that regulate the differentiation of endothelial cells. Activation of this receptor induces cell-cell adhesion.                                         SPHK pathway may play a role in the early placentation process and may be involved in the pathogenesis of preeclampsia ([@B20]).                                                                                              S1PR1 signaling regulates blood flow and pressure, induces cardiac hypertrophy and fibrosis and building of atherosclerotic plaques ([@B11]; [@B54]; [@B42]).                                                                                  Hypermethylated

  *CDKN1A*; cyclin dependent kinase inhibitor 1A        Regulator of cell cycle progression at G1. This protein also plays a regulatory role in S phase DNA replication and DNA damage repair.                                            Involved in cell growth, G1 arrest and apoptosis in endothelium from preeclamptic pregnancies ([@B4]; [@B26]).                                                                                                                Implicated in many cardiovascular processes, such as cardiac hypertrophy, proliferation and migration of vascular smooth muscle cells or M myocardial fibrosis ([@B48]; [@B56]; [@B70]).                                                       Hypermethylated

  *JAG2*; jagged 2                                      Activator of the Notch signaling pathway, an intercellular signaling mechanism essential for proper embryonic development.                                                        Involved in the regulation of trophoblast fate decisions, vasculogenesis and feto-maternal trafficking ([@B31]).                                                                                                              Role in cardiac regeneration process, ventricular chamber development and cardiomyopathy ([@B62]; [@B16]).                                                                                                                                     Hypomethylated

  *MEF2*; myocyte enhancer factor 2A                    DNA-binding transcription factor that activates muscle-specific, growth factor-induced, and stress-induced genes.                                                                 Dysregulated expression may be associated with placenta-related pregnancy disorders ([@B40]).                                                                                                                                 Key regulator of sprouting angiogenesis ([@B61]). Besides it plays a key role in cardiomyocyte survival ([@B30]).                                                                                                                              Hypomethylated
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

As a note of caution, the IPA results were obtained from an endothelium-restricted database of interactions, and thus the emergence of a cardiovascular pathway could be partially attributed to these presettings. However, our unrestricted STRING analyses also identified clear links to the cardiovascular system, such as the GO term "tube morphogenesis" that includes angiogenesis, or the Wnt signaling pathway known to regulate the mobilization and proliferation of cells in endothelium and epicardium in an ischemic heart ([@B53]; [@B18]), thus adding weight to the possible overlap of predisposing factors between preeclampsia, a hypertensive disorder, and the future risk of cardiovascular disease.

The altered methylation profile of fetal ECFC may have been present prior to the onset of clinical manifestations of preeclampsia. If already present, they could contribute to risk of preeclampsia. However, the changes could also be caused by the preeclampsia milieu, i.e., by oxidative stress and DNA oxidation ([@B75]; [@B32]; [@B24]).

To the best of our knowledge, our study is the first to explore whether the human intrauterine environment in preeclampsia is associated with abnormal fetal ECFC epigenetic gene network programming. These data suggest that fetal ECFC methylation status differs between preeclampsia and uncomplicated pregnancy. Our pathway analysis of the genes impacted by the methylation regulation may provide insights into possible mechanisms of pathogenesis. Future studies are needed to clarify which factors impact specific methylation changes, which methylation changes are involved in various obstetric complications, and what bearing these changes might have on offspring health.
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